InspireMD completes full exercise of Series H warrants for $17.9M gross proceeds

InspireMD, Inc.

Gross proceeds $17.9M; net proceeds $16.9M after fees.
Warrants exercised after positive one-year C-GUARDIANS trial follow-up.
Proceeds to fund CGuard Prime CAS delivery system and SwitchGuard TCAR NPS.
Participants include Marshall Wace, OrbiMed, Rosalind, Nantahala, Soleus, Velan, and Board members.
First of four milestone-based tranches from May 2023 private placement of up to $113.6M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.